上海微创心脉医疗科技（集团）股份有限公司 2025 年第二次临时股东会会议资料 证券代码：688016 证券简称：心脉医疗 上海微创心脉医疗科技（集团）股份有限公司 2025 年第二次临时股东会 会议资料 二零二五年十二月 | 2025 | 年第二次临时股东会会议须知 | 2 | | --- | --- | --- | | 2025 | 年第二次临时股东会会议议程 | 4 | | 2025 | 年第二次临时股东会会议议案 | 6 | | | 议案一：关于变更非独立董事暨新增非独立董事的议案 6 | | 上海微创心脉医疗科技（集团）股份有限公司 2025 年第二次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证会议的顺 利进行，根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司股 东会规则》以及《上海微创心脉医疗科技（集团）股份有限公司章程》、《上海微创心 脉医疗科技（集团）股份有限公司股东会议事规则》等相关规定，上海微创心脉医疗科 技（集团）股份有限公司（以下简称"公司"）特制定本次股东会会议须知： 一、为确认出席会议的股东或其代理人或其他出席者的出席资格， ...

截至2025年12月15日收盘，心脉医疗（688016）报收于91.05元，较前一交易日下跌0.33%，最新总市值 为112.23亿元。该股当日开盘90.88元，最高91.86元，最低90.8元，成交额达7160.64万元，换手率为 0.64%。 近日，心脉医疗发布公告称，公司将于2025年12月31日召开2025年第二次临时股东会，会议将采用现场 投票与网络投票相结合的方式进行，网络投票通过上海证券交易所系统开展。本次会议审议的议案包括 关于变更非独立董事暨新增非独立董事的议案，具体内容为选举孙洪斌、梁敏、刘旭东为第三届董事会 非独立董事。股权登记日为2025年12月24日，A股股东可参与投票。会议对中小投资者单独计票，不涉 及关联股东回避表决。 最新公告列表 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《心脉医疗：关于非独立董事辞任及补选非独立董事、选举董事长暨调整专门委员会成员的公 告》 《心脉医疗：关于召开2025年第二次临时股东会的通知》 ...

证券日报网讯12月15日晚间，心脉医疗发布公告称，同意选举孙洪斌为公司第三届董事会董事长。 ...

北京商报讯12月15日，心脉医疗发布公告称，公司董事长Jonathan Chen、董事霍庆福均因个人原因，申 请辞去各自担任的公司董事长、董事及董事会专门委员会相关职务，辞职后不再担任公司任何职务。 心脉医疗于12月15日召开董事会会议，同意将公司董事会人数由8名增加至9名，并同意提名孙洪斌、梁 敏、刘旭东为公司第三届董事会非独立董事候选人，同意选举孙洪斌为公司第三届董事会董事长，并以 2025年第二次临时股东会审议通过其为公司董事为生效前提，任期自其上任公司董事之日起至第三届董 事会任期届满之日止。 （文章来源：北京商报） ...

证券代码：688016 证券简称：心脉医疗 公告编号：2025-049 上海微创心脉医疗科技（集团）股份有限公司 关于非独立董事辞任及补选非独立董事、选举董事长 暨调整专门委员会成员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | | | | | | | 是否继 | 是否 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 存在 | | | | | | 原定任 | 离 | 续在上 | 未履 | | | | | | | 任 | 市公司 | | | 姓名 | 离任职务 | 离任时间 | | 期到期 | | | 行完 | | | | | | 日 | 原 | 及其控 | 毕的 | | | | | | | 因 | 股子公 | | | | | | | | | 司任职 | 公开 | | | | | | | | | 承诺 | | | 第三届董事会董事 | | | | 个 | | | | | 长、董事会战略与发 | 年 | | 2027 ...

证券代码：688016 证券简称：心脉医疗 公告编号：2025-050 （一） 股东会类型和届次 2025年第二次临时股东会 召开日期时间：2025 年 12 月 31 日 13 点 00 分 召开地点：上海市浦东新区康新公路 3399 弄 1 号楼 1 层公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 31 日 至2025 年 12 月 31 日 上海微创心脉医疗科技（集团）股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 股东会召开日期：2025年12月31日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （ ...

格隆汇12月15日丨心脉医疗(688016.SH)公布，公司董事长 Jonathan Chen 先生因个人原因申请辞去公司 董事长及董事会专门委员会的相关职务，辞职后将不再担任公司任何职务。 公司董事霍庆福先生因个人原因申请辞去公司董事及董事会专门委员会的相关职务，辞职后将不再担任 公司任何职务。 ...

Group 1 - The core viewpoint of the news is that Xinmai Medical (688016) has shown mixed financial performance in the third quarter of 2025, with a notable increase in revenue but a decline in net profit [2] - As of December 10, 2025, Xinmai Medical's stock closed at 91.62 yuan, with a slight increase of 0.22% and a trading volume of 8110 lots, amounting to a total transaction value of 73.91 million yuan [1] - The company reported a main revenue of 1.015 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 4.66%, while the net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2] Group 2 - In the third quarter of 2025, Xinmai Medical achieved a single-quarter revenue of 300 million yuan, which is a significant year-on-year increase of 64.68%, but the net profit attributable to shareholders fell by 23.63% to 114 million yuan [2] - The company has a debt ratio of 15.85% and reported an investment income of 11.6 million yuan, with financial expenses recorded at -7.86 million yuan and a gross profit margin of 70.4% [2] - Over the past 90 days, 9 institutions have provided ratings for the stock, with 7 buy ratings and 2 hold ratings, and the average target price set by institutions is 136.03 yuan [2]

Core Viewpoint - The stock of Xinmai Medical (688016) has shown a slight decline, with recent trading data indicating mixed capital flows among different investor categories, highlighting potential volatility in investor sentiment [1][2]. Group 1: Stock Performance - As of December 8, 2025, Xinmai Medical closed at 93.1 yuan, down 0.09% with a turnover rate of 0.72% and a trading volume of 8,897 lots, amounting to a total transaction value of 83.06 million yuan [1]. - Over the past five days, the stock has experienced fluctuations, with a notable increase of 1.28% on December 5, followed by a decline on subsequent days [2]. Group 2: Capital Flows - On December 8, 2025, the net inflow of main funds was 3.19 million yuan, accounting for 3.84% of the total transaction value, while retail investors saw a net outflow of 6.99 million yuan, representing 8.41% of the total [1][2]. - The recent five-day capital flow data indicates a trend of net outflows from retail investors, contrasting with net inflows from institutional and speculative funds on certain days [2]. Group 3: Financial Metrics and Industry Comparison - Xinmai Medical's total market capitalization is 11.476 billion yuan, with a net asset value of 3.982 billion yuan and a net profit of 429 million yuan, ranking 16th in the medical device industry [3]. - The company reported a gross margin of 70.4% and a net margin of 41.69%, significantly outperforming industry averages, with a price-to-earnings ratio of 20.06 compared to the industry average of 65.06 [3]. - For the first three quarters of 2025, Xinmai Medical's main revenue was 1.015 billion yuan, a year-on-year increase of 4.66%, while the net profit decreased by 22.46% [3]. Group 4: Analyst Ratings - In the last 90 days, nine institutions have provided ratings for Xinmai Medical, with seven recommending a buy and two suggesting an increase in holdings, indicating a generally positive outlook [4]. - The average target price set by institutions over the past 90 days is 136.03 yuan, suggesting potential upside from the current trading price [4].

Core Viewpoint - The stock of Xinmai Medical (688016) has shown a slight increase, with a closing price of 93.18 yuan on December 5, 2025, reflecting a 1.28% rise, while the overall market sentiment indicates a mixed flow of funds among different investor categories [1][2]. Financial Performance - For the first three quarters of 2025, Xinmai Medical reported a main business revenue of 1.015 billion yuan, a year-on-year increase of 4.66% [3]. - The net profit attributable to shareholders was 429 million yuan, representing a year-on-year decline of 22.46% [3]. - The company's gross profit margin stands at 70.4%, significantly higher than the industry average of 51.22% [3]. - The net profit margin is 41.69%, which is substantially above the industry average of 9.57% [3]. Market Position - Xinmai Medical's total market capitalization is 11.486 billion yuan, slightly above the industry average of 11.035 billion yuan [3]. - The company ranks 16th in net profit within the medical device industry, with a price-to-earnings ratio of 20.08, which is considerably lower than the industry average of 64.34 [3]. Recent Trading Activity - On December 5, 2025, the net outflow of main funds was 442.24 million yuan, accounting for 5.52% of the total transaction amount [1][2]. - Retail investors showed a net inflow of 544.67 million yuan, representing 6.80% of the total transaction amount on the same day [1][2]. Analyst Ratings - In the last 90 days, 9 institutions have rated Xinmai Medical, with 7 buy ratings and 2 hold ratings, indicating a generally positive outlook [4]. - The average target price set by analysts over the past 90 days is 136.03 yuan [4].